Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MRNA with free AI briefings, catalyst countdowns, and dilution alerts.

MRNA · Moderna, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8B Cash on Hand
23mo Cash Runway
10% Short Interest
$165.32 Analyst Target (19)
Follow MRNA by email Get an email when MRNA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MRNA, unsubscribe in one click. Privacy

📣 What MRNA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
VX-522 mRNA therapy Cystic Fibrosis Phase 1/2 · NCT05668741 Completed

Also used in these trials (approved or third-party drugs, not MRNA's own candidates): Ivacaftor.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MRNA holds $8B in cash and short-term investments (as of Sep 30, 2026) and burns about $1B/quarter from operations, an estimated runway of 23 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MRNA files for a raise →

👥 Who Owns MRNA

Insiders 5.4% Institutions (1356 holders) 77.5% Public and other holders 17.1%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 58,929,948 14.56% 2026-09-30
Blackrock Inc. Institution (13F) 27,797,163 6.87% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 25,933,824 6.41% 2026-03-31
Capital World Investors Institution (13G, 5%+) 22,276,996 5.51% 2026-06-30
Vanguard Portfolio Management LLC Institution (13F) 15,781,193 3.90% 2026-09-30
State Street Corporation Institution (13F) 15,471,910 3.82% 2026-09-30
Stephane Bancel
Chief Executive Officer, Director
Insider 13,005,140 3.21% 2026-08-05
BAILLIE GIFFORD & CO Institution (13F) 11,437,987 2.83% 2026-09-30
Geode Capital Management, LLC Institution (13F) 10,244,440 2.53% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 7,616,737 1.88% 2026-09-30
Noubar Afeyan
Director · +12,908 options
Insider 6,856,164 1.69% 2026-05-21
Theleme Partners LLP Institution (13F) 6,657,441 1.65% 2026-09-30

Share count 404,620,975 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-05
filed 2026-11-09
Andres Juan
Option award (A) 7,898 – –
2026-11-05
filed 2026-11-09
Andres Juan
Option award (A) 16,955 – –
2026-10-15
filed 2026-10-16
Hoge Stephen
Option exercise (M) 76,452 $12.21 1,675,710
2026-10-15
filed 2026-10-16
Hoge Stephen
Sale (S) 39,145 $220.72 1,636,565
2026-10-15
filed 2026-10-16
Hoge Stephen
Option exercise (M) 76,452 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-07-31 — NDA -17.3% -5.4% -7%

Browse all historical PDUFA outcomes →

Get the full MRNA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MRNA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.